Du, Yi

PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression

Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research

PARP inhibition in cancer therapyCancer Immunotherapy and Biomarkers

Cited by 981

KEAP1 E3 Ligase-Mediated Downregulation of NF-κB Signaling by Targeting IKKβ

Lee, D.-F., Kuo, H.-P., Liu, M., Chou, C.-K., Xia, W., Du, Y., Shen, J., Chen, C.-T., Huo, L., Hsu, M.-C., et al. (2009) · Molecular Cell

NF-κB Signaling PathwaysUbiquitin and proteasome pathways

Cited by 399

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling

Nahta, R., Yuan, L. X. H., Du, Y., & Esteva, F. J. (2007) · Molecular Cancer Therapeutics

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 267